Mureo Kasahara, Seisuke Sakamoto, Reiko Horikawa, Akinari Fukuda – 24 November 2018

Fabio Caputo, Marco Domenicali, Mauro Bernardi – 24 November 2018 – Between 14%‐30% of the world’s population is affected by alcohol use disorder (AUD), and excessive alcohol consumption represents the most common cause of liver disease in the western world. The clinical picture of alcoholic end‐stage liver disease is rendered extremely complex, as manifestations such as alcohol withdrawal syndrome, craving and physical dependence, as well as extrahepatic alcohol‐related diseases merge with the complications of advanced cirrhosis.

Shuet Fong Neong, Emma O. Billington, Stephen E. Congly – 23 November 2018 – Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction.

Shuet Fong Neong, Emma O. Billington, Stephen E. Congly – 23 November 2018 – Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction.

Elsa Solà, Cristina Solé, Pere Ginès – 23 November 2018

Esther A. Peterson, Zsuzsanna Polgar, Gnanapackiam S. Devakanmalai, Yanfeng Li, Fadi L. Jaber, Wei Zhang, Xia Wang, Niloy J. Iqbal, John W. Murray, Namita Roy‐Chowdhury, Wilber Quispe‐Tintaya, Alexander Y. Maslov, Tatyana L. Tchaikovskaya, Yogeshwar Sharma, Leslie E. Rogler, Sanjeev Gupta, Liang Zhu, Jayanta Roy‐Chowdhury, David A. Shafritz – 20 November 2018 – Hepatocyte transplantation is an attractive alternative to liver transplantation. Thus far, however, extensive liver repopulation by adult hepatocytes has required ongoing genetic, physical, or chemical injury to host liver.

Dagmar Kollmann, Nicolas Goldaracena, Markus Selzner – 18 November 2018

Alastair O’Brien – 17 November 2018 – Many studies have shown that 20% human albumin solution infusions improve circulatory function in patients with advanced liver disease, and this treatment is widely recommended and used by all hepatologists. However, it is more expensive than other crystalloids or colloids, and several countries suffer shortages of supply. This article examines whether other fluids might be considered for these patients.

Anna Suk‐Fong Lok – 15 November 2018 – Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains.

Maria G. Cardona‐Gonzalez, Jason D. Goldman, Lawrence Narayan, Diana M. Brainard, Kris V. Kowdley – 14 November 2018 – There are limited data on direct‐acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs.